Member Info for Bermudashorts

douve

I may be wrong but I think they just haven't updated the intro on their website - am certain that when they revise their valuation, they'll issue a new research note.

Stakis,

Result of the OO will be announced on 11th August

douve87

No, following the recent round of funding, Trinity Delta have suspended their valuation and will no doubt recalculate after the GM to reflect revised number of shares in issue together with any increase in valuation on any individual products.

achilles,

Redmile, a specialist biotech. /pharma fund hold over 90% of the shares here.

Fantastic news for Redx today and brilliant to see them finally rewarded for their efforts. Also great to see a traditional biotech, developing their own IP in their own labs, commercialising true UK innovation.

Chelsea/Balerno,

No the other companies due to present alongside Scancell went ahead on the original night. Scancell was the only one to move and have now joined a different group of companies for the One2One forum later in the month.

LL

In order to be entitled to take part in the OO, you must have been holding shares at close of play on 21st July. Anybody buying after this date won't qualify. Also shares for the placing and subscription won't be issued until after the GM (assuming all resolutions agreed) - think from memory they're expected to be admitted to trading on 12th August.

A paper by Chinese researchers was published last week looking at the gut microbiome, the gut-lung axis and respiratory diseases. Conclusion:- 'Increasing evidence suggests an important and complex crosstalk between the gut and lung, as well as between the gut microbiota and host immunity'

https://www.hindawi.com/journals/jir/2020/2340670/

Thanks for the replies.

Wild - enjoy!!

For some reason I can only see posts here up until 8.35am - nothing since. Have some been deleted by admin or is my lse playing up?

Slightly OT but as early clinical results are emerging from first Covid vaccines, it's looking hopeful that whilst they might not be perfect, one or some of them they may be enough to allow the return to some semblance of normality while we wait for 2nd generation vaccines to be developed.

I think we're now going to see an increasing focus on the logistics of vaccinating hundreds of millions of people and the hunt will be on for single dose vaccines that are easy to store and easy to administer - ie. a vaccine that requires a single shot by simple injection and can be stored at room temperature. With that in mind, this research from University of Swansea spin off , Innoture, shows what may be possible. They're devleoping a transdermal delivery system whereby COVID vaccines could be administered by individuals in their own home via a skin patch - what a difference that would make to the speed and cost of vaccinating whole populations.

This virus has been the catalyst for some amazing innovation from UK academia and industry.

https://www.med-technews.com/news/skin-patch-for-vaccine-self-administration-receives-welsh-go/

Look, if Redmile convert all of the CLNs, they'll hold approx 171m shares. The maximum they can hold is just under 217.5m before triggering rule 9 of the Takeover Code. That only leaves headroom of around 46m shares which sets a limit on how much Redmile can contribute to future funding rounds without being forced to make a mandatory offer for the Company. It's close - and David Evans was quite right to flag it. I suspect he also had in mind events at Redx when making that comment but the situation there was completely different to Scancell, very unusual and very complicated. The takeover by Redmile undoubtedly saved the Company from being forced to sell of their pipeline cheaply.

I've done quite a bit of research on Redmile which I will post at some stage and from what I can tell, they appear to be very supportive, understand the nature of the beast and take a long term view - just what Scancell need. I can find no other cases of Redmile buying their portfolio companies but don't take that as gospel.

So David Evans was quite right to mention the issue, we should all be aware of any risks and beyond that, there's plenty of information out there, it's up to each one of us to do our own research and make our own judgement calls.

Cars,

It's really hard to even guess because we actually have no idea what he's negotiating for - there are so many variables. could be any of the following :-

1) One or any combination of the 5 glycan mAbs with or without Avidimab enhancement
2) To develop one or any of the 5 as ADCs (antibody drug conjugates )
3) To develop one or more for CAR T cell therapy
4) The collaborator creates their own mAbs against Scancell's targets
5) Use of the whole Avidimab platform to enhance their own mAbs with their own targets
6) Each one of the above could be on an exclusive or non-exclusive basis, for any target or restricted to certain cancers, for any geographical location or restricted to a certain region/country. etc. etc.

If you're not talking about a full blown licensing deal but just a collaboration, then it sounds like there's some development work involved and it all depends who is doing what and how much resource is needed. If they managed to secure £10m for one mAb then I'd be surprised but delighted. I don't think that's unrealistic though when/if it comes to a licensing deal.

Sorry to be so vague and as ever, just my opinion based on the little we have been told about these collaborations.

Yes, that's true, the tweet on 24th July doesn't make sense - who knows? Could be anything but I'm pleased it has been postponed for reasons given in my earlier post.

Cars,

Yes, that's the one, thanks very much - appreciated.

It would be very disappointing if CH simply negotiated to extend an existing agreement. FWIW my own opinion is that the inclusion of the word 'commercial' suggests there is a financial element to any potential collaboration. It's not uncommon to see deals for a collaboration to develop 'x' number of targets with an option to license which are accompanied by upfront payments. Having said that, I think the wording is carefully designed to manage expectations and suggests we shouldn't be expecting a full blown licensing deal at this stage and I guess the monetary value of the deal will reflect that.

Just IMO of course.

WTP

Yes, it's not an interview but a standard investor event and Scancell's website has the slide sets from previous Proactive One2One events. Some excellent other companies are presenting at both events :)

I suspect it was booked way in advance and Scancell expected to have their funding completed. Think it would be more difficult to do an investor presentation when you're in the middle of a funding which has yet to be approved by shareholders and I'm pleased he has rescheduled. It makes much more sense to do the presentation after the results of the GM and the Open Offer are confirmed and when the new shares are admitted to trading. That's the point where you want to boost sentiment and work on you IR.

botski,

Being lazy here but have you the wording of the whole sentence to hand?

Slightly OT but those who are watching the race for the first generation Covid-19 vaccines might be interested in the article below which explains why BioNTech selected BNT162b2 from its 4 candidates to take into phase 3 trials. Sounds promising for older people.

'generating immune responses against more parts of the spike protein may translate into "more consistent responses across diverse populations and in older adults."'

Also worth noting that BioNTech/Pfizer who have received no funding, have agreed to supply their vaccine to the US Government at $19.50 per shot. Moderna on the other hand have received around $1 billion in funding from the US Government (ie. taxpayer) intend to charge between $50 and $60 per shot for what many consider to be an inferior vaccine.

https://www.biopharmadive.com/news/biontech-pfizer-start-phase-3-coronavirus-vaccine-trial/582405/

Konar,

Well it certainly can't harm their chances although it's just looking at one aspect (CD8+ T cells) and in a relatively small number of patients. I don't know whether you read the whole paper but they also mentioned the fact that even though it only targets just the spike protein, 80% of patients from BioNTech's mRNA phase I clinical trial produced CD8+ T cells. It seems that there's so much still to learn and understand and all these research papers seem to be small parts of the jigsaw helping to reveal the whole picture. So far, it seems that each piece further validates Scancell's approach.

On a slightly different note, the WHO have changed the format of their vaccine tracker. It now gives details of dosing frequency and intervals and as you can see, the vast majority require at least 2 doses. The Oxford vax is still showing 1 dose but I know they're also testing 2 doses and in animal models a 2 shot regime has produced better results.

https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

Konar,

Yes, for those who haven't read it, the study is looking at which SARS-CoV-2 epitopes are recognised by memory CD8+ T cells.

- only 3 of the 29 epitopes were located in the S protein with most located in ORF1ab
- the highest density were located in the N protein
- pre-existing immunity from the common cold coronaviruses doesn't give T cell based protection from SARS-CoV-2 but there is cross-reactivity with long lasting SARS (2003) memory T cells
- 90% of the CD8+ T cell reactivity was directed at epitopes outside the S protein
- testing for CD8+ T cells can potentially be done at scale and may provide an alternative/additional diagnostic test
- The smaller proteins N, M, and ORF3a also appear strongly and broadly immunogenic.

In short, the study supports Scancell's approach in developing a vaccine which targets the N (nucleocapsid) protein as well as the S protein.